Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose methotrexate.

@article{Janka1987EarlyIT,
  title={Early intensification therapy in high-risk childhood acute lymphocytic leukemia: lack of benefit from high-dose methotrexate.},
  author={Gritta E. Janka and Kurt Winkler and Herbert Juergens and Ulrich Goebel},
  journal={Haematology and blood transfusion},
  year={1987},
  volume={30},
  pages={
          456-60
        }
}
The prognosis for acute lymphoblastic leukemia (ALL) in childhood has improved considerably in the last two decades. Intensive chemotherapy soon after diagnosis has made a major contribution to this success [3, 12, 14], especially in patients with adverse prognostic factors [6]. In COALL-80, a cooperative West German treatment study for ALL, high-risk patients received intensive combination chemotherapy after a modification of the West Berlin protocol BFM 79/81 [7]. In the subsequent study… CONTINUE READING